| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Hemokinin 1 (human) targets the tachykinin neurokinin 1 (NK1) receptor as a selective full agonist. It also acts as a full agonist at NK2 and NK3 receptors. The NK1 receptor is a G-protein coupled receptor involved in various physiological processes including pain transmission, inflammation, and smooth muscle contraction.
|
|---|---|
| ln Vitro |
In vitro, Hemokinin 1 (human) induces proliferation of B-cells and exhibits antiapoptotic actions on these cells. It shows high selectivity for the NK1 receptor over NK2 and NK3 receptors, with IC50 values demonstrating approximately 200-fold selectivity for NK1 compared to NK3 and over 260-fold compared to NK2.
|
| ln Vivo |
In vivo, Hemokinin 1 (human) exhibits antihypertensive activity. It can produce opioid-independent analgesia. The peptide's biological effects are mediated through activation of tachykinin receptors, which are widely distributed in the central and peripheral nervous systems.
|
| Enzyme Assay |
Receptor binding affinity is typically determined using radioligand binding assays with membrane preparations from cells expressing human NK1, NK2, or NK3 receptors. Membranes are incubated with radiolabeled substance P or other tachykinin ligands and varying concentrations of the test peptide. IC50 values are calculated from competition binding curves.
|
| Cell Assay |
Cell-based assays utilize B-cell cultures to assess proliferative and antiapoptotic effects. Cells are treated with varying concentrations of Hemokinin 1 (human), and proliferation is measured using standard methods such as MTT assay or BrdU incorporation. Apoptosis is evaluated through flow cytometry or caspase activity assays.
|
| Animal Protocol |
For in vivo studies, Hemokinin 1 (human) is typically administered via intravenous or intraperitoneal injection in rodent models. Blood pressure is monitored to evaluate antihypertensive effects. Analgesic activity is assessed using standard pain models such as the hot plate or tail flick tests.
|
| ADME/Pharmacokinetics |
As a peptide, Hemokinin 1 (human) is expected to have a short half-life in circulation due to rapid proteolytic degradation by peptidases. Peptide drugs generally require formulation strategies such as PEGylation or encapsulation to improve pharmacokinetic properties. The compound should be stored desiccated at -20degC.
|
| Toxicity/Toxicokinetics |
Toxicity data for Hemokinin 1 (human) are limited. Peptide-based research compounds generally exhibit low toxicity at pharmacological doses, though careful handling is recommended. Standard safety precautions for laboratory handling of peptides apply, including the use of appropriate personal protective equipment.
|
| References | |
| Additional Infomation |
Hemokinin 1 (human) is a research-use peptide not approved for therapeutic applications. It is related to substance P and belongs to the tachykinin peptide family. The compound is synthesized via solid-phase peptide synthesis and purified by HPLC. References include studies by Bellucci et al. (2002) and Zhang et al. (2000) on its pharmacological profile and role in B lymphopoiesis.
|
| Molecular Formula |
C54H84N14O14S
|
|---|---|
| Molecular Weight |
1185.39516
|
| Exact Mass |
1183.59
|
| CAS # |
491851-53-7
|
| Related CAS # |
Hemokinin 1, human TFA
|
| PubChem CID |
71311766
|
| Appearance |
White to off-white solid powder
|
| Density |
1.282 g/cm3
|
| Boiling Point |
1669.168ºC at 760 mmHg
|
| Flash Point |
963.278ºC
|
| LogP |
1.087
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
39
|
| Heavy Atom Count |
83
|
| Complexity |
2150
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)N)O
|
| InChi Key |
NYBLUYYRUFKGTB-XJCFQSCISA-N
|
| InChi Code |
InChI=1S/C54H84N14O14S/c1-30(2)24-38(51(79)64-35(46(58)74)21-23-83-5)63-44(73)27-59-48(76)39(25-33-14-8-6-9-15-33)66-52(80)40(26-34-16-10-7-11-17-34)67-50(78)37(19-20-42(56)71)65-53(81)41(29-69)68-47(75)31(3)61-49(77)36(18-12-13-22-55)62-43(72)28-60-54(82)45(57)32(4)70/h6-11,14-17,30-32,35-41,45,69-70H,12-13,18-29,55,57H2,1-5H3,(H2,56,71)(H2,58,74)(H,59,76)(H,60,82)(H,61,77)(H,62,72)(H,63,73)(H,64,79)(H,65,81)(H,66,80)(H,67,78)(H,68,75)/t31-,32+,35-,36-,37-,38-,39-,40-,41-,45-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]acetyl]amino]hexanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pentanediamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8436 mL | 4.2180 mL | 8.4360 mL | |
| 5 mM | 0.1687 mL | 0.8436 mL | 1.6872 mL | |
| 10 mM | 0.0844 mL | 0.4218 mL | 0.8436 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
